Grifols leverages its biopharmaceuticals division to raise profit to €227M in the first half
The Catalan multinational company has revenues exceeding €3,500M and consolidates the new organizational structure
BarcelonaGrifols earned 227 million euros during the first half of this year, 28.2% more than in the same period of the previous fiscal year. The Catalan multinational of plasma-derived medicines attributes the improvement, in large part, to the evolution of its biopharma division, its main source of income. According to the results published this Tuesday to the National Securities Market Commission (CNMV), the turnover of this area reached 3,148 million euros by June, 5.4% more year-on-year at constant exchange rates.
In the same vein, the group's total revenues increased to 3,574 million euros, 2.6% more at constant exchange rates. The presentation of the results comes in a context marked by the consolidation of the company's new structure, with two clearly differentiated organizations to strengthen the operational and financial independence of the subsidiaries: one for the biopharma business in the United States, and the other for the rest of the world.
Beyond the new management formula, Grifols continues to work to expand into new markets in Africa and the Middle East. In this regard, the project the company is developing in Egypt, together with the country's government, constitutes "a fundamental pillar" within the strategy to diversify plasma supply. As the multinational points out, Egypt will become "the company's main source of plasma outside the United States." This is why Grifols announced last June an investment of 460 million euros by 2029.
According to the company's CEO, Nacho Abia, the first-half results are a testament to the "continued strength of the business" and the "disciplined execution" of the group's strategy.
Changes in financial result
Another of the reasons that have led Grifols to improve its semi-annual results has to do with the financial result, the difference between financial income (such as dividends or interest in favor) and financial expenses (such as bank fees or interest on debts), which, despite remaining in the red, was better: between January and June 2026, Grifols lost 218 million euros for this concept, a figure that improves the losses of 312 million euros corresponding to the same period of 2025.
According to Grifols' Chief Financial Officer, Rahul Srinivasan, this first half-year has allowed the group to "reinforce financial flexibility", and has placed it in a "solid" position to "confidently" execute its long-term strategy.